Credit: Shutterstock photoShares of Insmed Inc. INSM more than doubled in pre-market trading Tuesday after the company announced that its new drug, an inhaled antibiotic known as Alis, successfully treated patients with a rare lung disease.
Alis met the main goal in a late-stage study involving 336 adult patients with nontuberculous mycobacterial lung infections. According to Insmed, the addition of the drug showed statistically significant reduction in bacterial density by month six in 29% of patients, compared to just 9% in patients receiving the standard treatment.
After closing at $12.29 per share on Friday afternoon, Insmed soared more than 140% in pre-market trading, opening at $29.50 per share as investors returned from the Labor Day holiday on Tuesday.
Nontuberculous mycobacterial lung infections are caused by a specific type of bacteria found in soil and water, which causes cough, fever and blood in the mucus. As of right now, there is no approved treatment for these type of infections.
Based on the latest data, Insmed now plans to apply for accelerated approval for Alis. The FSA had previously fast-tracked the drug and granted it breakthrough therapy designation.
Want morestock market analysisfrom this author? Make sure to follow @ Ryan_McQueeney on Twitter!
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Insmed, Inc. (INSM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
